Editas Medicine Inc (NASDAQ:EDIT) price on Thursday, March 20, fall -1.44% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $1.37.
A look at the stock’s price movement, the close in the last trading session was $1.39, moving within a range at $1.33 and $1.42. The beta value (5-Year monthly) was 1.873. Turning to its 52-week performance, $8.44 and $1.12 were the 52-week high and 52-week low respectively. Overall, EDIT moved -57.19% over the past month.
Editas Medicine Inc’s market cap currently stands at around $113.68 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Mar-04.
The average forecast suggests down to a -30.74% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 10.83M, representing a -66.47% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that EDIT is a 50% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
9 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 3 analyst(s) rate the stock as a Hold, 6 recommend EDIT as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
EDIT’s current price about -17.75% and -8.90% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 44.11, while 7-day volatility ratio is 8.12% and 14.90% in the 30-day chart. Further, Editas Medicine Inc (EDIT) has a beta value of 2.10, and an average true range (ATR) of 0.22. Analysts have given the company’s stock an average 52-week price target of $9, forecast between a low of $5 and high of $10. Looking at the price targets, the low is -264.96% off current price level while to achieve the yearly target high, price needs to move -629.93%. Nonetheless, investors will most likely welcome a -556.93% jump to $9 which is the analysts’ median price.
If we refocus on Editas Medicine Inc (NASDAQ:EDIT), historical trading data shows that trading volumes averaged 2.06 over the past 10 days and 4.04 million over the past 3 months. The company’s latest data on shares outstanding shows there are 82.73 million shares.
The 0.91% of Editas Medicine Inc’s shares are in the hands of company insiders while institutional holders own 62.52% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 13.77 million on 2025-02-28, giving us a short ratio of 2.31. The data shows that as of 2025-02-28 short interest in Editas Medicine Inc (EDIT) stood at 2097.9999 of shares outstanding, with shares short falling to 17.09 million registered in 2025-01-31. Current price change has pushed the stock 7.87% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the EDIT stock continues to rise going into the next quarter.
